Why Eswatini's Cannabis Exports Keep Stalling at the SA Border
Photo by Wolfgang Vrede via Pexels.
Eswatini has no port. It has no cargo air route that connects directly to Rotterdam, Frankfurt, or any of the medical cannabis hubs that matter to an export business. Every legal shipment leaving the country has to physically pass through South Africa first, whether it's heading to a European pharmaceutical buyer or a processing facility two provinces away. That's not a metaphor for bureaucratic friction -- it's the literal geography of a landlocked kingdom of roughly 1.2 million people wedged between a much larger neighbor and the Indian Ocean coastline it can't reach on its own.
That single fact of geography forces every exporter to satisfy two separate regulatory systems that were never designed to talk to each other. Eswatini issues its own permits under its own drug laws. South Africa, once the crop crosses the border, applies its own narcotics and export documentation regime, built around a different legal framework and a different set of international obligations. Getting cleared in Mbabane doesn't get you cleared in Pretoria, and the paperwork doesn't automatically transfer.
The country's sole licensed cannabis operator, PSIQ, got its approval back in 2019 -- a ten-year exclusive license to grow, process, import, and export. Years later, there's still no confirmed track record of steady export volumes reaching international buyers. Eswatini has cheap land, a climate well suited to cannabis cultivation, and a government that said yes to a commercial operator seven years ago. What it doesn't have is a finished export pathway, and the reasons for that have as much to do with unfinished legislation and institutional turf disputes as with any outright ban on the plant itself.
A Landlocked Country With No Way Out But South Africa
Photo by Amina B via Pexels.
Eswatini sits entirely enclosed by two neighbors: South Africa wraps around roughly three-quarters of its border, and Mozambique covers the rest. There is no coastline, no deepwater port, and nothing resembling a major international cargo airport. Matsapha Airport, just outside Manzini, handles regional passenger traffic and some freight, but it isn't wired into the kind of temperature-controlled, chain-of-custody cargo networks that pharmaceutical-grade cannabis exports typically require. That leaves land border posts into South Africa, and to a lesser extent Mozambique, as the only realistic exit routes for anything grown legally inside the country.
All of those crossing points -- Matsapha's cargo terminal included -- fall under close watch from the Eswatini Revenue Service, which treats cannabis movement as a trafficking risk category regardless of whether the shipment carries a government export permit. A legal consignment and an illegal one physically travel the same roads and pass through the same checkpoints, which means legitimate exporters inherit a layer of scrutiny built for interdiction, not facilitation.
Eswatini and its neighbor Lesotho both offer growers something attractive: land is inexpensive, labor costs are low, and domestic cultivation rules are comparatively light touch compared to the compliance-heavy markets of Western Europe or North America. But that cost advantage gets eaten up almost immediately by thin compliance infrastructure -- neither country has built out the kind of verification systems that international buyers expect under the UN's narcotics control conventions, which track controlled substances from seed to sale with documentation standards most small Southern African regulators simply haven't resourced yet.
One cannabis operator working across the region put it bluntly: the simplest and safest route to international markets is often to fly product out of South Africa directly, skipping the home-country export step entirely by relocating cultivation or at least processing across the border. That's a quiet admission that, for a company trying to actually move product rather than wait on policy, Eswatini's export mechanism is currently more liability than asset.
Two Regulators, One Shipment: The Compliance Math
Photo by MedPoint 24 via Pexels.
Clearing Eswatini's own permitting process is only step one. Once a shipment physically crosses into South Africa, it needs to satisfy an entirely separate set of narcotics control and export documentation requirements -- one that doesn't automatically recognize or defer to whatever Eswatini's government already approved. In practice, this means two full regulatory reviews stacked on top of each other, run by two agencies with no formal mechanism for cross-recognition.
Part of the friction comes down to paper trail. International buyers, and South African customs and narcotics authorities alike, expect documentation that traces a cannabis shipment back through cultivation records, testing results, and chain-of-custody logs consistent with UN narcotics convention standards. Eswatini-origin cannabis often arrives at the border without that depth of record-keeping already built in, since the domestic permitting system wasn't constructed with those downstream expectations in mind. The result is that verification work gets pushed to after the border crossing rather than completed before it, adding delay exactly where exporters can least afford it.
Complicating things further, Eswatini-grown cannabis has a long, well-documented history of being trafficked illegally into South Africa, long before any legal export program existed. That history hasn't gone away just because a licensed operator now has government paperwork. South African border and narcotics authorities apply heightened scrutiny to any Eswatini-origin shipment, legal or not, simply because the illegal trade volume across that same border has historically dwarfed anything moving through official channels.
All of this lands hardest on operators who don't have dedicated compliance teams. A larger multinational cannabis company can absorb the cost of hiring staff fluent in both countries' regulatory language, tracking two sets of deadlines, and managing two separate relationships with government agencies. A smaller Eswatini-based grower, or a newer entrant trying to break into the market, often can't. The dual-regime burden isn't evenly distributed -- it functions as a de facto barrier to entry that favors whoever already has deep pockets and legal counsel on both sides of the border.
The 1922 Law Still on the Books
Photo by Eric Prouzet via Unsplash.
The legal foundation for all of this is, on paper, over a century old. Cannabis remains illegal in Eswatini under the 1922 Opium and Habit-Forming Drugs Act, a statute drafted during the British colonial administration, decades before the country gained independence in 1968. It has never been fully replaced, only amended and worked around, which means Eswatini's modern cannabis policy is still legally anchored to a law written for an entirely different era and an entirely different set of concerns.
Trafficking convictions under the Act are not a minor matter -- sentences can run up to fifteen years, among the more severe penalty structures in the region for drug offenses. Import and export of cannabis for recreational purposes remain formally prohibited outright, with enforcement resting on the Eswatini Revenue Service at Matsapha Airport and the land border posts into South Africa and Mozambique.
Reform has been in motion, slowly. Back in 2020, the health ministry tabled a bill to establish a Medicines Regulatory Authority, which among other things would have given that new regulator the power to import, export, and wholesale cannabis products itself. It sounded straightforward on paper, but it created an obvious structural problem: the same body meant to license and oversee private cannabis companies would also be competing with them commercially.
Saladin Magagula, chair of the Eswatini Cannabis Association, raised exactly that objection -- a regulator can't credibly act as referee and player in the same game, licensing its own export operations while simultaneously deciding whether private competitors get licensed at all. That conflict-of-interest critique has stuck, and it's a meaningful part of why the bill has sat stalled in parliament for roughly six years, neither passed nor formally abandoned.
Where the Drafting Stands Now
Photo by Jolame Chirwa via Unsplash.
As of August 2026, ownership of the reform effort has shifted. It's no longer the health ministry driving the legislation -- Eswatini's Agriculture Ministry has taken over drafting of a replacement bill, and this version is scoped narrowly to medical and industrial cannabis only. Agriculture Minister Mandla Tshawuka confirmed on August 7 that adult-use cannabis is explicitly excluded from the new draft, closing the door on any near-term recreational market and keeping the legislative conversation focused on export-oriented medical and industrial applications.
No parliamentary debate has taken place yet. The ministry's public line is that drafting is progressing well, though that kind of language tends to mean the bill hasn't reached a stage where its actual text is being argued over by lawmakers -- it's still an internal ministry document, not yet a parliamentary one.
A separate cross-country regulatory survey, published roughly eleven days before Tshawuka's confirmation, backs up where things currently stand: Eswatini's existing law only permits ministerial licensing for specified medical purposes, on a case-by-case approval basis, with the broader reform still sitting in proposed rather than enacted form. That's consistent with what PSIQ's seven-year-old exclusive license actually represents -- a ministerial carve-out, not a general legal framework other companies can simply plug into.
The handoff from health ministry to agriculture ministry is worth paying attention to beyond just procedural trivia. It suggests the earlier Medicines Regulatory Authority model, with its built-in conflict of interest that Magagula flagged, may have been quietly shelved or substantially redesigned rather than simply delayed. Agriculture ministries don't typically inherit drug scheduling and licensing authority unless the previous approach has been judged unworkable. Whether that produces a cleaner bill remains to be seen, since none of the actual text has reached public or parliamentary scrutiny yet.
South Africa's Own Bottleneck Makes Things Worse
Although 120 companies hold SAHPRA export licenses, only about 20—roughly one-sixth—are actually exporting regularly, highlighting a large gap between licensing and active trade activity.
Even if Eswatini solved every piece of its own legislative puzzle tomorrow, the shipment would still have to clear South Africa -- and South Africa's own export system is far from finished. The South African Health Products Regulatory Authority, SAHPRA, has issued 120 export licenses for medicinal cannabis. That sounds like a substantial, functioning industry. But the broader legal framework meant to support it, the Cannabis for Private Purposes Act, is still not in force.
Public comment on that Act's regulations closed on March 5, 2026, and Parliament still has to approve the final rules before the law is fully implemented. Until that happens, South Africa's export system operates in a kind of legal limbo -- licenses exist, but the regulatory scaffolding they're supposed to sit on isn't complete.
The gap between licenses issued and licenses actually used is stark. Industry sources estimate that of the dozens of SAHPRA license holders, only around 20 export product on anything resembling a regular basis. The rest are sitting on paperwork without a functioning commercial pathway behind it.
Plenty of those license holders aren't just waiting quietly. Many are reportedly selling into grey markets just to generate cash flow while the formal export system remains unfinished -- a survival strategy, not a long-term business model, but a telling sign of how much pressure the regulatory delay puts on operators who've already invested in compliance.
That matters enormously for Eswatini. If South African operators who already hold the right domestic licenses are struggling this much to move product through legal export channels, then Eswatini-origin cannabis -- which requires an additional layer of cross-border documentation just to be recognized as legitimate once it crosses into South Africa -- faces an even steeper climb to reach the same ports and buyers.
PSIQ and the Promise of 2019
PSIQ's 2019 approval looked, at the time, like Eswatini's entry point into the global medical cannabis trade. The government granted the company a dedicated farm and processing plant, plus a ten-year exclusive license covering research, cultivation, import, export, and distribution -- about as comprehensive a mandate as a single operator can be handed under Eswatini's permitting system.
Seven years into that license, there's no recent reporting confirming that PSIQ has reached anything resembling consistent cross-border export volumes. That doesn't necessarily mean the company has failed outright -- cultivation and processing infrastructure may well be functioning domestically. But as the country's sole commercial operator with export authority, PSIQ's visibility problem is itself informative. If the one company holding every relevant permit the government can offer still isn't producing a confirmed, steady flow of legal exports years later, that points to something deeper than a single firm's execution -- it points to the structural bottleneck running through both the Eswatini-South Africa compliance gap and the unresolved legislative questions covered above.
Meanwhile, the advantages that made Eswatini look attractive for cannabis investment in the first place -- the warm, consistent climate suited to outdoor and greenhouse cultivation, land costs well below those in Western Europe or North America, proximity to South Africa's larger consumer and industrial base -- remain largely theoretical as export assets. They're real, but they're not translating into actual shipments reaching international buyers at scale, because the legal and logistical infrastructure to move product hasn't caught up with the growing conditions that make Eswatini a plausible cultivation site in the first place.
None of this traces back to a shortage of growing capacity or a lack of interest from international buyers. Eswatini has land, climate, and at least one company with a full suite of government permits. What it doesn't have is legal clarity arriving simultaneously in two capitals, and right now neither Mbabane nor Pretoria has finished its half of the job.
Until South Africa's Cannabis for Private Purposes Act moves from approved regulations to an actually functioning legal system, and until Eswatini's agriculture ministry bill clears a parliament that has already let one version of this reform sit untouched for six years, any export permit issued on either side of that border solves only half the problem. A shipment can be perfectly legal leaving Eswatini and still run into a South African system that isn't built to receive it smoothly, or vice versa.
The thing worth watching isn't one bill or one regulatory announcement in isolation -- it's whether the agriculture ministry's drafting timeline and South Africa's implementation of the Cannabis for Private Purposes Act start moving on parallel tracks. Progress on just one side of that border won't unstick the crop sitting at it. Progress on both, arriving at roughly the same time, is the only combination that actually changes what happens at Matsapha Airport and the land crossings into South Africa.
